Grant of Options

RNS Number : 4361R

Synairgen plc

06 July 2022

 

Synairgen plc

('Synairgen' or the 'Company')

Grant of Options

Southampton, UK - 6 July 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that on 5 July 2022 the Board of Synairgen granted options ('Options') over 6,407,130 ordinary shares of one pence each in the capital of the Company ('Ordinary Shares') at an exercise price of one pence per Ordinary Share. The Options represent in aggregate 3.18 per cent. of the Company's issued share capital. 

Following this grant, Synairgen has 14,891,262 options in issue, representing 7.39 per cent. of the Company's issued share capital.

Certain Options were issued to Directors of the Company and Persons Discharging Managerial Responsibilities ('PDMR'):

	Options issued  5 July 2022	Total options	Ordinary shares	Total interest	Percentage holding of fully diluted share capital
Directors
Richard Marsden1	534,482	2,813,995	995,771	3,809,766	1.76%
Dr. Phillip Monk	387,931	2,034,254	423,934	2,458,188	1.14%
John Ward	387,931	2,160,889	734,092	2,894,981	1.34%
PDMRs
Jody Brookes	515,000	979,166	-	979,166	0.45%
Brooke Clarke2	515,000	628,636	8,520	637,156	0.29%
Richard Francis	515,000	628,636	-	628,636	0.29%
Richard Hennings	515,000	757,568	-	757,568	0.35%
Gareth Walters	515,000	635,779	-	635,779	0.29%

1.  Richard Marsden's shareholding includes 184,821 shares held in his pension plan.

2.  Brooke Clarke's shareholding is held by her spouse.

The Options are issued under the Company's Long Term Incentive Plan and are exercisable up to 4 July 2032, subject to the achievement of appropriate performance criteria which match the criteria for the 2021 award as set out on page 24 of the 2021 annual report.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No. 596/2014 ('MAR')

For further enquiries, please contact:

Synairgen plc

Brooke Clarke, Head of Communications

[e-mail]

Tel: + 44 (0) 23 8051 2800

finnCap (NOMAD and Joint Broker)

Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)

Alice Lane, Sunil de Silva (ECM)

Tel: + 44 (0) 20 7220 0500

Numis Securities Limited (Joint Broker)

James Black, Freddie Barnfield, Duncan Monteith

Tel: + 44 (0) 20 7260 1000

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott, Namrata Taak, Lucy Featherstone

[e-mail]

Tel: [phone]

MKC STRATEGIES, LLC (US Media Relations)

Mary Conway

[e-mail]  

Tel: [phone]

Notes for Editors

About Synairgen

Synairgen is a UK-based respiratory company focused on drug discovery, development and commercialisation. The Company's primary focus is developing SNG001 (inhaled interferon beta) for the treatment of severe viral lung infections, including COVID-19, as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs. SNG001 has been granted Fast Track status from the US Food and Drug Administration (FDA). Founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com .

1.	Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')
a)	Name	Richard Marsden
2.	Reason for notification
a)	Position / status	Chief Executive Officer
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Synairgen plc
b)	LEI	213800IMMTOPPDF8HD24
4.	Details of the transaction(s):
a)	Description of the financial instrument Identification code	Options over ordinary shares of 1p each GB00B0381Z20
b)	Nature of the transaction	Award of Options under the Company's share plans
c)	Price(s) and volume(s)	534,482 Options awarded
d)	Aggregated information Aggregated volume Price	n/a
e)	Date of the transaction	5 July 2022
f)	Place of the transaction	Outside a trading venue

1.	Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')
a)	Name	Dr Phillip Monk
2.	Reason for notification
a)	Position / status	Chief Scientific Officer
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Synairgen plc
b)	LEI	213800IMMTOPPDF8HD24
4.	Details of the transaction(s):
a)	Description of the financial instrument Identification code	Options over ordinary shares of 1p each GB00B0381Z20
b)	Nature of the transaction	Award of Options under the Company's share plans
c)	Price(s) and volume(s)	387,931 Options awarded
d)	Aggregated information Aggregated volume Price	n/a
e)	Date of the transaction	5 July 2022
f)	Place of the transaction	Outside a trading venue

1.	Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')
a)	Name	John Ward
2.	Reason for notification
a)	Position / status	Chief Financial Officer
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Synairgen plc
b)	LEI	213800IMMTOPPDF8HD24
4.	Details of the transaction(s):
a)	Description of the financial instrument  Identification code	Options over ordinary shares of 1p each GB00B0381Z20
b)	Nature of the transaction	Award of Options under the Company's share plans
c)	Price(s) and volume(s)	387,931 Options awarded
d)	Aggregated information Aggregated volume Price	n/a
e)	Date of the transaction	5 July 2022
f)	Place of the transaction	Outside a trading venue

1.	Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')
a)	Name	Jody Brookes
2.	Reason for notification
a)	Position / status	Head of Clinical Operations
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Synairgen plc
b)	LEI	213800IMMTOPPDF8HD24
4.	Details of the transaction(s):
a)	Description of the financial instrument Identification code	Options over ordinary shares of 1p each GB00B0381Z20
b)	Nature of the transaction	Award of Options under the Company's share plans
c)	Price(s) and volume(s)	515,000 Options awarded
d)	Aggregated information Aggregated volume Price	n/a
e)	Date of the transaction	5 July 2022
f)	Place of the transaction	Outside a trading venue

1.	Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')
a)	Name	Brooke Clarke
2.	Reason for notification
a)	Position / status	Head of Communications
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Synairgen plc
b)	LEI	213800IMMTOPPDF8HD24
4.	Details of the transaction(s):
a)	Description of the financial instrument Identification code	Options over ordinary shares of 1p each GB00B0381Z20
b)	Nature of the transaction	Award of Options under the Company's share plans
c)	Price(s) and volume(s)	515,000 Options awarded
d)	Aggregated information Aggregated volume Price	n/a
e)	Date of the transaction	5 July 2022
f)	Place of the transaction	Outside a trading venue

1.	Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')
a)	Name	Richard Francis
2.	Reason for notification
a)	Position / status	Head of CMC
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Synairgen plc
b)	LEI	213800IMMTOPPDF8HD24
4.	Details of the transaction(s):
a)	Description of the financial instrument Identification code	Options over ordinary shares of 1p each GB00B0381Z20
b)	Nature of the transaction	Award of Options under the Company's share plans
c)	Price(s) and volume(s)	515,000 Options awarded
d)	Aggregated information Aggregated volume Price	n/a
e)	Date of the transaction	5 July 2022
f)	Place of the transaction	Outside a trading venue

1.	Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')
a)	Name	Richard Hennings
2.	Reason for notification
a)	Position / status	Chief Commercial Officer
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Synairgen plc
b)	LEI	213800IMMTOPPDF8HD24
4.	Details of the transaction(s):
a)	Description of the financial instrument Identification code	Options over ordinary shares of 1p each GB00B0381Z20
b)	Nature of the transaction	Award of Options under the Company's share plans
c)	Price(s) and volume(s)	515,000 Options awarded
d)	Aggregated information Aggregated volume Price	n/a
e)	Date of the transaction	5 July 2022
f)	Place of the transaction	Outside a trading venue

1.	Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')
a)	Name	Gareth Walters
2.	Reason for notification
a)	Position / status	Chief Regulatory Officer
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Synairgen plc
b)	LEI	213800IMMTOPPDF8HD24
4.	Details of the transaction(s):
a)	Description of the financial instrument Identification code	Options over ordinary shares of 1p each GB00B0381Z20
b)	Nature of the transaction	Award of Options under the Company's share plans
c)	Price(s) and volume(s)	515,000 Options awarded
d)	Aggregated information Aggregated volume Price	n/a
e)	Date of the transaction	5 July 2022
f)	Place of the transaction	Outside a trading venue

 

END

 

 

DSHEAEXSEAPAEAA